Oppenheimer Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $200
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson has maintained an Outperform rating on Neurocrine Biosciences (NASDAQ:NBIX) and increased the price target from $170 to $200.

March 13, 2024 | 12:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Jay Olson reaffirmed an Outperform rating on Neurocrine Biosciences and raised the price target from $170 to $200.
The increase in price target by a reputable analyst like Jay Olson from Oppenheimer is a strong positive signal for investors, indicating a bullish outlook on the stock. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100